{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:16Z","timestamp":1792190596146,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.eprac.2024.11.012","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T17:03:04Z","timestamp":1733158984000},"page":"373-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prospects and Challenges of Immunotherapy for Thyroid Cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Ping","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqin","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-4202","authenticated-orcid":false,"given":"Dingcun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2024.11.012_bib1","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib2","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1158\/1078-0432.CCR-15-2998","article-title":"Nivolumab and pembrolizumab for non-small cell lung cancer","volume":"22","author":"Morgensztern","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eprac.2024.11.012_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.11.012_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/his.13230","article-title":"CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy","volume":"71","author":"Zwaenepoel","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.eprac.2024.11.012_bib6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive screening for PD-L1 expression in thyroid cancer","volume":"24","author":"Ahn","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eprac.2024.11.012_bib7","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2024.11.012_bib8","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0144","article-title":"Combinatorial Hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer","volume":"13","author":"Tan","year":"2024","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.eprac.2024.11.012_bib9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","article-title":"Driving CAR T-cells forward","volume":"13","author":"Jackson","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.eprac.2024.11.012_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"Cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.eprac.2024.11.012_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","article-title":"Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment","volume":"25","author":"Gajewski","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.eprac.2024.11.012_bib13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eprac.2024.11.012_bib14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","article-title":"Visualizing synaptic transfer of tumor antigens among dendritic cells","volume":"37","author":"Ruhland","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eprac.2024.11.012_bib15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eprac.2024.11.012_bib16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41556-022-01024-5","article-title":"IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8(+) T cells to overcome immunotherapy resistance in cancer","volume":"24","author":"Bae","year":"2022","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.eprac.2024.11.012_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo5409","article-title":"Interleukin-2-based therapies in cancer","volume":"14","author":"Raeber","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib18","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib19","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2024.11.012_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib23","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/thy.2019.0086","article-title":"A\u00a0phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2024.11.012_bib24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","article-title":"Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer","volume":"22","author":"Kollipara","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to\u00a0kinase\u00a0inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.eprac.2024.11.012_bib26","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/1078-0432.CCR-21-0822","article-title":"Phase II, randomized study of spartalizumab (PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent\/metastatic nasopharyngeal cancer","volume":"27","author":"Even","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eprac.2024.11.012_bib27","first-page":"138","article-title":"Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer","volume":"12","author":"Iwasaki","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib28","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2217\/fon-2018-0557","article-title":"A\u00a0Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer","volume":"15","author":"Takahashi","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.859013","article-title":"Immune checkpoint protein expression defines the prognosis of advanced thyroid carcinoma","volume":"13","author":"Luo","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.012_bib31","doi-asserted-by":"crossref","first-page":"407","DOI":"10.62347\/EJAA3388","article-title":"Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation","volume":"14","author":"Su","year":"2024","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.eprac.2024.11.012_bib32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11864-024-01219-y","article-title":"Promising therapeutic targets for recurrent\/metastatic anaplastic thyroid cancer","volume":"25","author":"Abdalla","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1010279","article-title":"Thyroid-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Chera","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.012_bib34","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1503\/cmaj.180870","article-title":"Adverse events associated with immune checkpoint inhibitor treatment for cancer","volume":"191","author":"Esfahani","year":"2019","journal-title":"CMAJ"},{"key":"10.1016\/j.eprac.2024.11.012_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.012_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib38","first-page":"269","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors","volume":"81","author":"Deligiannis","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.eprac.2024.11.012_bib39","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.012_bib40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.eprac.2024.11.012_bib41","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1002\/cam4.3410","article-title":"Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-020-00881-7","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J\u00a0Exp Clin Cancer Res"},{"key":"10.1016\/j.eprac.2024.11.012_bib44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib45","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eprac.2024.11.012_bib46","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib47","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.eprac.2024.11.012_bib48","article-title":"CAR-T cell therapy in advanced thyroid cancer: from basic to clinical","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.eprac.2024.11.012_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-46938-7","article-title":"Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy","volume":"9","author":"Vedvyas","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2024.11.012_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.omto.2021.01.012","article-title":"Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4","volume":"20","author":"Bhoj","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.eprac.2024.11.012_bib51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40164-022-00311-z","article-title":"Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer","volume":"11","author":"Ding","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","author":"Zhao","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.eprac.2024.11.012_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.eprac.2024.11.012_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aak9702","article-title":"Blockade of surface-bound TGF-beta on regulatory T cells abrogates suppression of effector T cell function in the\u00a0tumor\u00a0microenvironment","volume":"10","author":"Budhu","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.eprac.2024.11.012_bib55","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eprac.2024.11.012_bib56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell\u00a0therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-med-061119-015600","article-title":"Toward better understanding and management of CAR-T cell-associated toxicity","volume":"72","author":"Schmidts","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib58","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier\u00a0disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eprac.2024.11.012_bib59","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.eprac.2024.11.012_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.eprac.2024.11.012_bib62","doi-asserted-by":"crossref","first-page":"19550","DOI":"10.1021\/acsnano.3c05635","article-title":"mRNA cancer vaccines: construction and boosting strategies","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.eprac.2024.11.012_bib63","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2024.11.012_bib64","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jcem.86.10.7949","article-title":"Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination","volume":"86","author":"Schott","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2024.11.012_bib65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.eprac.2024.11.012_bib66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jconrel.2024.05.020","article-title":"Neoantigens and cancer-testis antigens as promising vaccine candidates for triple-negative breast cancer: delivery strategies and clinical trials","volume":"370","author":"Malla","year":"2024","journal-title":"J\u00a0Contr Release"},{"key":"10.1016\/j.eprac.2024.11.012_bib67","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.eprac.2024.11.012_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143296","article-title":"Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response","volume":"131","author":"von Locquenghien","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2024.11.012_bib69","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1102495","article-title":"CD8 T cell priming in the presence of IFN-alpha renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy","volume":"189","author":"Hervas-Stubbs","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.eprac.2024.11.012_bib70","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.eprac.2024.11.012_bib71","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.eprac.2024.11.012_bib72","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/ERC-17-0532","article-title":"Immune landscape of papillary thyroid cancer and immunotherapeutic implications","volume":"25","author":"Na","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.eprac.2024.11.012_bib73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000227450","article-title":"Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors","volume":"52","author":"Lissoni","year":"1995","journal-title":"Oncology"},{"key":"10.1016\/j.eprac.2024.11.012_bib74","first-page":"4250","article-title":"IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto's thyroiditis overcomes immune escape in vitro","volume":"11","author":"Hu","year":"2020","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.eprac.2024.11.012_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.929091","article-title":"What is the status of immunotherapy in thyroid neoplasms?","volume":"13","author":"Garcia-Alvarez","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eprac.2024.11.012_bib76","article-title":"A\u00a0distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer","volume":"9","author":"Han","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.eprac.2024.11.012_bib77","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.eprac.2024.11.012_bib78","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.eprac.2024.11.012_bib79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.eprac.2024.11.012_bib80","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:50:01Z","timestamp":1741027801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1530891X24008401"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospects and Challenges of Immunotherapy for Thyroid Cancer","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}